CSPC Group announced that the phase II clinical trial of SYS6026 injection developed by the group to treat high-grade cervical squamous intraepithelial lesions related to human papillomavirus type 16 or 18 has been officially launched in China. This product is a therapeutic mRNA vaccine. The registered category is therapeutic biological product class 1, and its target is HPV16 and 18 subtype E6 and E7 protein antigens. As a new non-surgical treatment option, this product is expected to provide new treatment options for HPV16 or type 18 related HSIL.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.